Leite Ana Rita, Angélico-Gonçalves António, Leite-Moreira Adelino, Neves João Sérgio, Ferreira João Pedro
RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.
Department of Endocrinology, Diabetes and Metabolism, São João Local Health Unit, Porto, Portugal.
J Hum Hypertens. 2025 May 3. doi: 10.1038/s41371-025-01021-9.
Plasma renin is a surrogate marker of sodium retention in hypertension, and its levels are suppressed in conditions of heightened aldosterone production. We performed a random-effects meta-analysis of randomized clinical trials focusing on the impact of mineralocorticoid receptor antagonists (MRA) and aldosterone synthase inhibitors (ASi) on blood pressure according to baseline renin levels. We included four randomized clinical trials, and we found that the response to MRA or ASi was independent of baseline plasma renin levels.
血浆肾素是高血压患者钠潴留的替代标志物，在醛固酮生成增加的情况下其水平会受到抑制。我们针对盐皮质激素受体拮抗剂（MRA）和醛固酮合酶抑制剂（ASi）根据基线肾素水平对血压的影响进行了一项随机临床试验的随机效应荟萃分析。我们纳入了四项随机临床试验，发现对MRA或ASi的反应与基线血浆肾素水平无关。
